Imprimir esta página

Ventajas de los iSGLT2

  • 03 Enero 2018

Francisco Javier Ortega Ríos
Médico de familia (Zamora). redGDPS-SED

 

7DM877 FARMACOLOGIA

 

Bibliografía
1. Inzuchi SE. et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcomes trials. Diab Vasc Dis Res 2015: 12;90-103
2. Zinman B, et al. for the EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373:2117-2128.
3. Neal B, et al. for the CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377:644-657
4. Kosiborod M, et al. on behalf of the CVD-REAL Investigators and Study Team. Lower rates of hospitalization for heart failure and all-cause death in new users of SGLT-2 inhibitors versus other glucose lowering drugs – Real world data from six countries and more than 300.000 patients: The CVD-REAL Study. ACC.17. 66th Annual Scientific Session & Expo. Washington 19 marzo 2017.
5. Storgaard H, et al. (2016) Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLoS ONE 11(11): e0166125. doi:10.1371/journal. pone.0166125
6. Abdul-Ghani M, et al. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? Diabetes Care. 2017 Jul;40(7):813-820. doi: 10.2337/dc16-2736

Valora este artículo
(2 votos)
  • Modificado por última vez en 04 Ene 2018, 07: 45
Ventajas de los iSGLT2 - 4.5 out of 5 based on 2 votes

Artículos relacionados (por etiqueta)